Generation of myeloid and lymphoid cells from progenitors involves dynamic changes in transcription factor expression and use, and disruption of hematopoietic transcription factor function and expression can contribute to leukemic transformation. PU.1 and Ikaros are pivotal factors whose expression and utilization are dynamically altered during hematopoietic development. Here, we demonstrate that expression of PU.1, encoded by the Sfpi1 gene, is divergently regulated by Ikaros in distinct cell type-specific contexts. Chromatin immune precipitation analysis and functional perturbations revealed that Ikaros can directly repress or activate Sfpi1 transcription via different PU.1 cis-elements, with PU.1 and Ikaros collaborating at myeloid-specific elements but not at other elements. Our results thus shed light on how PU.1 and Ikaros can act as lineage competency factors to facilitate both myeloid and lymphoid developmental programs.
INTRODUCTION
The proto-oncogene PU.1, upregulated in virally induced erythroleukemias, is an Ets family transcription factor encoded by the Sfpi1/Spi-1 gene. 1 PU.1 has critical roles in multiple hematopoietic cell types 2, 3 and has emerged as a key determinant regulating cell-type specification. Higher PU.1 dosage restricts erythrocyte specification and enables generation of committed myeloid progenitors or joint myeloid/lymphoid progenitors, the lymphoid-primed multipotent precursors (LMPP). 2, 4 Expressed at the LMPP stage, PU.1 levels rise in myeloid progenitors, but fall in prepro-B-cells. 5, 6 Differences in PU.1 level strongly affect specification of myeloid versus B-cells from LMPPs. 7 However, PU.1 deficiency blocks both myeloid and B-cell development, and reduced PU.1 dosage promotes acute myeloid leukemia. 8, 9 Thus, precise transcriptional controls of PU.1 expression are required.
The mechanisms controlling PU.1 expression as LMPPs become myeloid or B-cells remain unclear. PU.1 positively autoregulates by binding the Sfpi1 promoter and URE, a compound enhancer element located B14 kb upstream of the Sfpi1 transcriptional start site. 10 --13 Additional myeloid-specific enhancers have also been found between the upstream regulatory element (URE) and the promoter. 14, 15 A recently proposed gene regulatory network model for the differential control of PU.1 expression in B-cell versus myeloid specification suggests that attenuation of PU.1 autoregulation by two transcription factors, Gfi-1 and Ikaros, can regulate these cell fate decisions. 13 Many cell types that depend on PU.1 also depend on Ikaros. However, the optimal ratios of these two factors diverge in myeloid and B lymphoid lineages, 16 and it is unclear whether Ikaros and PU.1 work collaboratively or antagonistically. Ikaros is a lineage determinant with a critical role in priming the lymphoid developmental program in hematopoietic stem cells and progenitors, and mice lacking Ikaros also develop myeloid hyperproliferation. 17, 18 The dominant negative Ikaros isoform 6 has been linked with acute myeloid leukemia. 19 Although PU.1 and Ikaros collaborate to control at least one important target in LMPPs, 20, 21 genetic evidence suggests that Ikaros opposes PU.1 to support Bcell development over alternative myeloid programs. 13, 22 Indeed, expression of a dominant negative version of Ikaros in erythroid cells increased PU.1 levels. 23 Because of the central position of both factors in lymphoid developmental gene networks, and their roles in leukemia, it is crucial to resolve whether Ikaros is indeed a direct repressor of PU.1.
Here, we show that Ikaros binds distinct subsets of Sfpi1 ciselements, including the URE, in myeloid and B lineage cells. Whereas Ikaros suppresses URE activity in pre-B-cells, we show that Ikaros is a cell-type-specific URE activator in myeloid cells. Furthermore, we find that Ikaros, PU.1 and RNA polymerase II (Pol II) are co-recruited and collaborate to drive activation through additional myeloid-specific enhancers. These results resolve the bifunctional role of Ikaros in PU.1 regulation through lineagespecific recruitment to distinct cis-elements that direct both Ikaros and PU.1 functional specificity.
RESULTS AND DISCUSSION
An B3 kb DNA fragment, CE5-CE3, is a myeloid enhancer lacking B-cell regulatory function After PU. 1 is expressed in LMPPs, its levels diverge between myeloid and lymphoid cells. 5 We recently described a Sfpi1 cis-regulatory region, CE5-CE3, which had cell-type-specific functions. The CE5 element, on its own or as part of CE5-CE3, was an enhancer in a myeloid cell line but not in a pro-T-cell line.
14 To determine whether this function is myeloid specific or common to all PU.1-expressing cells, we tested CE5-CE3 function in B lineage cells.
Reporter constructs were made to test segments of the Sfpi1 upstream region joined to the Sfpi1 promoter element, CE1 (Figure 1a) . In NFS-25 pre-B-cells, the construct containing CE5-3 URE~3 kb   CE9  CE10  CE8  CE3  CE1  CE5 CE4  CE7/6   0   1   2   3   4   5   6   7   LB  L53  L89  L1  L76  LB  L53  L98  L1 Reporter constructs were designed as described previously. 14 (b) Transient transfection assays showing Sfpi1 reporter activity in NFS-25 pre-B-cells and RAW264.7 macrophages. Data represent the average fold difference relative to L1. NFS-25 data are from five independent experiments. RAW264.7 data shown are from a single representative experiment performed in triplicate. Error bars represent standard deviations. Cells were transfected using FuGENE (Roche, Indianapolis, IN, USA) at a 3:1 DNA:FuGENE ratio. NFS-25 cells were grown in RPMI media with 10% fetal bovine serum, penicillin/streptomycin/glutamine, non-essential amino acids, sodium pyruvate and 50 mM 2-mercaptoethanol. RAW264.7 cells were grown in Dulbecco's modified Eagle media with 10% fetal bovine serum and penicillin/streptomycin/glutamine. Transfected cells were harvested 30 --48 h after transfection. Cells were co-transfected with Renilla Luciferase control plasmid (pRL-CMV) and lysates were analyzed using Promega's Dual Luciferase system (Promega Corporation, Madison, WI, USA). (c) The CE5-CE3 fragment is a myeloid-specific enhancer when integrated into chromatin. Cell lines were stably transfected with the L9-6 and L9-3 constructs depicted in Figure 1a . Bars show the geometric mean of six independent mixed pools (dots) of stably transfected cells 30 days after transfection. Data are reported as relative light units. P-value is from student's t-test of log 10 -transformed data. FuGENE:DNA complexes were formed, then the same complexes were aliquoted to 6-well plates containing either NFS-25 or RAW264.7 cells. For stable transfections, Sfpi1 reporters were linearized with Not I before transfection. The renilla luciferase was cloned into pTracer EF/Bsd A (Invitrogen, Carlsbad, CA, USA, Cat#V88920) and the construct was linearized with Fsp I for co-transfection with Sfpi1 reporters. Cells were selected with 5 --15 mg/ml of Blasticidin for their duration in culture, beginning one day after transfection. (d) Multigenome alignments and transcription factor target site prediction analysis of the CE5 and CE7/6 regions are shown. TRANSFAC analysis was performed through the Biobase TRANSFAC suite's MATCH tool (https://www.portal.biobaseinternational.com/cgi-bin/portal/login.cgi). Predicted hematopoietic transcription factors with matrix similarity matches 40.9 are shown (black). Some matches o0.9 are also shown (gray). CBF ¼ core-binding factor sites for the Runx family. 'Ets'-labeled sites are general Ets family sites that potentially bind to multiple Ets family factors. Asterisks mark conserved sites present in only 4/6 aligned sequences. All other sites are present in all six sequences. The boxed sequence shows a region of CE5 with a PU.1 target site adjacent to a specifically predicted Ikaros target site. The red bar represents the DNA probe CE5-P2, designed for gel shift assays ( Figure 3 ). ChIP assays were performed using anti-PU.1 antibody (sc-352 from Santa Cruz Biotechnology (Santa Cruz, CA USA)). ChIP assays were performed based on Upstate's protocol exactly as described previously.
14 Data shown in all ChIP panels are from three or more independent experiments. Orange and purple bars in each panel show data for positive control regions of reported PU.1 target genes Mef2c and Il7r. Panels with red bars are from myeloid cells (RAW264.7). Panels with blue bars are from pre-B-cells (NFS-25). Panels with green bars represent data from pro-T-cells (Adh.2C2). Primer pairs used for each region are labeled on the X axis and the primer sequences are reported in.
14 ChIP-enriched DNA was analyzed by q-PCR in triplicate for each experiment. Individual ChIP experiments were normalized first to input DNA then normalized against a region that lacked enrichment to provide relative fold enrichment. Independent experiments were then averaged. Error bars show standard deviations. Iterative one-way analysis of variance (ANOVA) was used to analyze ChIP data. ANOVA was initially performed with all regions. If ANOVA generated a P-value o0.01, data for 'regions of interest' were removed from the initial ANOVA test group, and ANOVA was repeated on data from the remaining regions until these generated P40.1. The regions remaining in the test group that lacked a statistically significant enrichment difference were then used as a control group against which to compare the removed 'regions of interest' individually by T-tests. The resulting P-values were adjusted using the Bonferroni correction method, and regions with Po0.0005 were marked by asterisks in ChIP data figures. (b) Elf-1 ChIP assays using anti-Elf-1 antibody sc-631 are shown as described. (c) GABPa ChIP assays using anti-GABPa antibody sc-22810 is shown as described. (d) Ets-1 ChIP assays using anti-Ets-1 antibodies sc-22802 and sc-111are shown as described. (e) RNA polymerase II (Pol II) ChIP analyses are shown as described, using anti-Pol II antibody ab5408 from AbCam (Cambridge, MA, USA).
(L5-3) generated similar luciferase expression as L1, the promoter only construct, but in RAW264.7 myeloid cells L5-3 produced strongly enhanced reporter expression (Figure 1b) . In contrast, the conserved URE elements CE9 and CE8 within the L98 reporter enhanced luciferase expression similarly in pre-B and myeloid cells alike (Figure 1b) . Cell-type-specific CE5-CE3 activity was also demonstrated in a chromatin context in stably transfected cell lines. We tested reporters comprising the URE and CE7/6, either without CE5-CE3 (L9-6) or with it (L9-3). L9-6 generated similar luciferase expression in pre-B and myeloid cells. However, L9-3 gave stronger reporter activity only in the myeloid cells (Figure 1c) , implying that CE5-CE3 enhancer activity is myeloid restricted.
CE5 and CE7/6 are myeloid-restricted PU.1 target elements To identify potentially important transcription factor-binding sites within CE5, we used TRANSFAC to analyze regions of CE5 that were conserved in multigenome alignments. As the CE7/6 region may contribute to myeloid-specific PU.1 regulation, 15 we also examined CE7/6. The most frequently predicted sites in both CE5 and CE7/6 are overlapping Ikaros and Ets family sites (Figure 1d ). Ikaros is a bifunctional transcription factor able to activate or repress transcription, and Ikaros can compete with Ets factors for the same sites. 24 Ikaros, which is required for B-cell development, might constrain PU.1 expression by blocking PU.1 autoregulation through the URE. 13 However, in our myeloid and B-cell lines the URE drove similar levels of reporter activity. Thus, the myeloidspecific enhancer activity of CE5-CE3 and its predicted Ets family sites suggested that myeloid-restricted PU.1 autoregulation could contribute to the functional specificity of CE5-CE3.
PU.1 chromatin immune precipitation (ChIP) in fact revealed cell-type-specific patterns of PU.1 occupancy at Sfpi1 regions. PU.1 bound the promoter region (CE1) in myeloid cells (Figure 2a , red panel) as previously reported, 11 but that binding was weak compared with the strong PU.1 binding at the URE elements CE9 and CE8 in these cells (Figure 2a, red panel) . PU.1 also bound CE8 in pre-B-cells (Figure 2a, blue panel) , as well as known PU.1 target genes, Mef2c and Il7r, in both PU.1-expressing cell lines (red and blue panels); 25, 26 Adh.2C2 pro-T cells, which lack PU.1, showed no binding (green panel). However, only in the myeloid cells was strong PU.1 binding found at CE5 and CE7/6 (Figure 2a,  arrows) . (Figures 2b --d) . 27 The URE can recruit Pol II-containing complexes in PU.1-expressing cells. 28, 29 Pol II association with other Sfpi1 regions was also cell-type-specific. Pol II occupied CE8 in all cell lines tested, but bound to the promoter (CE1) only in PU.1-expressing cells (Figure 2e) . Significantly, however, Pol II bound CE5 and CE7/6 only in the myeloid cells (Figure 2e, arrows) . These results support a functional role for CE5 in myeloid-specific PU.1 regulation as well as CE7/6. . Surprisingly, Ikaros did bind CE7/6 and CE5 too, but only in myeloid cells (Figure 3a, red panel, arrows) .
The cell-type-specific Ikaros association patterns observed imply distinct, context-specific rules for Ikaros recruitment. PU.1 but not Ikaros bound Il7r in RAW264.7 (Figure 2a) , whereas Ikaros occupied Il7r in Adh.2C2 cells that lack PU.1 expression (Figure 3a, green panel, arrow) . Thus, Ikaros-binding strength is determined separately from PU.1 at Il7r. In contrast, the unique pattern of Ikaros occupancy of Sfpi1 sites in the myeloid cells suggested that Ikaros recruitment to CE5 and CE7/6 in RAW264.7 cells might involve co-occupancy with bound PU.1.
PU.1 can recruit Ikaros DNA binding
To test whether PU.1 binds concomitantly with Ikaros at the CE5 sites, a DNA probe was made from the CE5 region (CE5-P2) to span adjacent sites predicted to bind PU.1 and Ikaros (Figure 1d , Figure 3 . Cell-type-specific binding of Ikaros with PU.1 at Sfpi1 cis-regulatory elements. (a) Ikaros binds the URE region in RAW264.7 and NFS-25 cells, but binds other regions with cell-type-specificity. Ikaros ChIP assays were performed using antibodies Santa Cruz sc-13039 and Active Motif #39291 (Carlsbad, CA, USA). Data are presented as in Figure 2. (b, c) The CE5 region nucleates cell-type-specific myeloid complexes in vitro that contain PU.1 and Ikaros proteins. (b) Probe CE5-P2 (see Figure 1d ) and CE5-P2m2 (Ikaros site mutated; see Figure 4a for mutated sequence) were radiolabeled and incubated with nuclear extracts from RAW264.7 cells (M) or NFS-25 cells (B). Preparation of nuclear extracts and binding conditions were described in. 14 Complexes were resolved by 6% SDS --PAGE, dried, and then exposed to film. Myeloid-specific complexes are labeled M1, M2 and M3. Anti-PU.1 and anti-Ikaros antibodies used in gel shift experiments are sc-352 and Active Motif #39291, respectively. The overlapping PU.1/Ikaros-binding site was mutated in probe CE5-P2m1. The exact sequences mutated for m1 and m2 are shown in red in the schematic in Figure 4a . Competitor DNA probes were used at 250-fold molar excess; 4 mg of antibodies were used as labeled. (c) PU.1 can direct formation of a PU.1 and Ikaros-containing complex on probe CE5-P2. TnT Couple Quick Transcription/Translation system (Promega # L1171 and L2081) was used to generate PU.1, Ikaros or 'Plastic' proteins. RAW264.7 nuclear extract was included (lane 1) for comparison. All other lanes contained equal volumes of reticulocyte lysate (treated or untreated). For treated lysates, 1 mg of plasmid DNA was incubated with lysates to generate proteins following manufacturer's protocol. A 10-mg of total lysate were run per lane. (d) Western blot of Ikaros and Sp1 protein. Nuclear extracts (2 --8 mg) from Adh.2C2 and Raw264.7 cells were separated on an 8% SDS --PAGE gel. This blot had been previously probed for Sp1 and was shown in. 14 The blot was stripped and reprobed here with anti-Ikaros antibody (sc-13039). (e) Adh.2C2 cells transduced with PU.1 retroviral vector express high levels of PU.1 mRNA. Retroviral vector supernatants were prepared by transfection of pMX-PU.1-IRES-hCD8 plasmid into Phoenix-Eco packaging cells with FUGENE 6 reagent. Virus particle-containing medium was collected at 48 --72 h after transfection. Adh.2C2 cells were subsequently transduced to express PU.1 using the TAKARA RetroNectin method (TAKARA Bio Inc, Otsu, Shiga, Japan). RNA was prepared using Trizol (Invitrogen) and manufacturer's protocol. cDNA were prepared from RNA using the Superscript III system (Invitrogen #18080 --400), then analyzed for PU.1 sequence by quantitative real-time PCR. PU.1 levels were normalized against glyceraldehyde 3-phosphatases. Data are plotted on a log 10 box). The CE5-P2 probe nucleated myeloid-specific complexes in gel shift experiments (Figure 3b, lanes 1 --6 vs. 7 --12; M1, M2 and M3). M1, M2 and M3 contained PU.1 because anti-PU.1 antibody supershifted those complexes (Figure 3b, lane 5) . Additionally, an anti-Ikaros antibody blocked formation of the PU.1 containing M1 complex (lane 6). Mutation of the overlapping PU.1/Ikaros site (mutated in CE5-P2m1) destroyed the ability to compete for the myeloid complexes (lanes 2 and 3) . Although mutation of the Ikaros-specific site in CE5-P2m2 did not prevent competition for M1, M2 and M3 (lane 4), it did prevent probe CE5-P2m2 from nucleating these complexes itself (lanes 13 --18) . Thus, distinct PU.1 and Ikaros-binding sites in CE5 may collaborate to form myeloid-specific PU.1 --Ikaros complexes. Similar results were found with a probe spanning predicted Ikaros-PU.1-Ikaros sites in CE7/6 (data not shown).
Ikaros could be recruited to CE5-P2 using in vitro translated PU.1, generated in a reticulocyte lysate transcription/translation system. Lysate containing PU.1 could form complex M1 whereas 
Competitors: Ab: (Figure 3c, lanes 2 and 3; arrow) . In this system, which contains endogenous Ikaros, 31 the M1 complex was sensitive to both anti-PU.1 and anti-Ikaros antibodies (lanes 8 and 9) . Furthermore, formation of the M1 complex by PU.1 was also blocked by addition of in vitro translated 'Plastic', a dominant negative point mutant of Ikaros that heterodimerizes with wild-type Ikaros family members to inhibit DNA binding 32 (lane 6). Thus, PU.1 and Ikaros binding to CE5 can be coordinate, not competitive.
Effect of PU.1 dose on recruitment of PU.1 and Ikaros to Sfpi1 sites in vivo The CE5 site where PU.1 and Ikaros co-bind in myeloid cells is not bound by the myeloid driver C/EBPa. 15 We therefore tested whether high dose PU.1 alone is sufficient to bind and recruit Ikaros to this site. Adh.2C2 pro-T-cells, which normally express no PU.1 but X2 Â more Ikaros protein than RAW264.7 cells (Figure 3d (Figure 3e) , and the ectopic PU.1 strongly bound to Mef2c, Il7r and both URE elements (Figure 3f ). The presence of PU.1 in PU.1-transduced Adh.2C2 cells now enabled Ikaros to be recruited to CE9 (Figure 3g ), in contrast to untransduced cells (Figure 3a) . Ikaros also bound Il7r more strongly (Figure 3g) . Additionally, Pol II now also bound CE9 and Il7r in the Adh.2C2 þ PU.1 cells (Figure 3h) .
However, despite the high dose, PU.1 did not bind CE5 and could only weakly bind CE7/6, similar to NFS-25 cells. Similarly, the myeloid-specific elements where PU.1 and Ikaros bind together were not occupied efficiently by either factor in the PU.1-overexpressing lymphoid cells. Thus, high-level PU.1 is not the sole determinant involved in cell-type-specific CE5 and CE7/6 activity.
PU.1 and Ikaros-binding sites are required for CE5 enhancer activity Gel shift analysis resolved potential PU.1 and Ikaros target sites within CE5 that might be required for CE5 enhancer activity. We tested the functional contribution of those sites by constructing additional L5-3 reporters harboring mutations in these CE5 sites (Figure 4a ). When the m1 and m2 sites, required for the PU.1-and Ikaros-containing M1 complex (Figure 3b ), were mutated in L5-3m1-2, enhancer activity in myeloid cells was abolished (Figure 4a ). Additionally, mutation of another overlapping PU.1/ Ikaros site in CE5 also abolished CE5-3 enhancer activity (L5-3m4). In contrast, mutation of a predicted C/EBP family site (L5-3m3) did not affect reporter activity. These results indicate that joint PU.1 and Ikaros sites are required at CE5 for its myeloid cell-specific enhancer function. PU.1 mediates CE7/6-CE5 enhancer activity To establish whether the myeloid-specific PU.1 binding is functional, we compared the effects of PU.1 knockdown on the activities of L98 with a reporter that contains both CE7/6 and CE5 joined to the PU.1 promoter (L7-5). Antisense morpholinos (E1 and E2) that target different PU.1 exon/intron boundaries eliminated detectable PU.1 protein expression in myeloid cells, as compared with a nonspecific control morpholino (Figure 4b ). PU.1 knockdown not only reduced L98 activity by B40% (Figure 4c ), as expected, but also completely abolished the enhancer function of L7-5 ( Figure 4c) . Thus, while the URE is PU.1 responsive but partially PU.1-independent, CE7-CE5 strictly requires PU.1 for enhancer activity in these myeloid cells.
Lineage-specific effects of Ikaros on Sfpi1 cis-elements: positive regulation in myeloid cells but inhibitory activity in pre-B-cells To determine why Ikaros, a suspected inhibitor of PU.1 expression, should be specifically corecruited to CE7-CE5 under conditions where these elements act as enhancers, we tested the effect of neutralizing Ikaros in distinct cellular contexts, by transfecting Sfpi1 cis-element driven luciferase reporters into B and myeloid cells with empty vector or the 'Plastic'-dominant negative mutant of Ikaros. Figure 4d shows that indeed, co-transfection of B-lineage cells with Plastic to neutralize endogenous Ikaros enhances reporter expression driven by the URE (L98), consistent with a repressive role for Ikaros in these cells. In contrast, however, co-transfection with Plastic strongly reduced the activity of the L98 and L7-5 reporters in myeloid cells (Figure 4e) . Thus, by co-occupancy of CE5 and CE7/6 with PU.1, Ikaros is a positive regulator of Sfpi1 in macrophages.
CONCLUSION
These results show that PU 1 and Ikaros factors can act both as collaborators and as antagonists in different cellular contexts, based on their cell-type-specific recruitment to distinct subsets of their potential DNA target sites (Figure 4f ). The sites examined here for lineage-specific differential recruitment of PU.1 and Ikaros are all conventionally recognizable on the basis of established position weight matrices, but engagement by these factors is highly context dependent. At the myeloid-specific cis-regulatory elements of Sfpi1, neither PU.1 nor Ikaros is sufficient to establish binding in the NFS-25 pre-B or Adh.2C2 pro-T cell lines, yet these elements can mediate potent positive regulation in myeloid cells dependent on both PU.1 and Ikaros. Crucially, the ability of Ikaros to bind with PU.1 at the CE8-CE9 elements themselves is associated with opposite functional consequences in B and myeloid cells. Thus, not only can lineage determinants affect when and where Ikaros will bind DNA, but these distinct patterns of recruitment confer an additional layer of cell-type-specific regulatory interaction, which allows Ikaros' functional contributions to be reversed in distinct developmental contexts.
